Iambic Therapeutics Inc. shares soared 16% in its trading debut after the clinical-stage cancer drugmaker and technology firm raised $150 million in a US initial public offering.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.